Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 6/20 | 0.48 |
| ▸ | ECE1 | P42892 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614011 | 0.86 | HSD17B10 (0.57) | HSD17B10MMEECE1ACE2MMP3 | |
| SCHEMBL1764165 | 0.84 | ECE1 (0.51) | MMEECE1MMP3 | |
| SCHEMBL1763964 | 0.79 | HSD17B10 (0.55) | HSD17B10MMEECE1ACE2MMP3 | |
| SCHEMBL1764401 | 0.79 | ACE2 (0.60) | MMEECE1ACE2MMP3MMP1 | |
| SCHEMBL7613048 | 0.76 | HSD17B10 (0.58) | HSD17B10MMEECE1ACE2MMP3 | |
| SCHEMBL1764577 | 0.75 | ERAP2 (0.43) | MME | |
| SCHEMBL10305302 | 0.75 | LMNA (0.61) | LMNASMN1; SMN2MMP3HTTMMP1 | |
| SCHEMBL863804 | 0.75 | LMNA (0.65) | HSD17B10LMNASMN1; SMN2HTTSLC1A3 | |
| SCHEMBL5916357 | 0.74 | HSD17B10 (0.52) | HSD17B10MMP3 | |
| SCHEMBL7619188 | 0.74 | ACE2 (0.72) | MMEECE1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2018-11-20 | — | — | US | disclosed |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS (FR) | 2014-06-12 | — | — | US | disclosed |
| US-8703747-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | HSD17B10 521/4885MME 3670/4885ECE1 4157/4885 |
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | OPRM1, HRH3, HRH4 | HSD17B10 548/4885MME 3490/4885ECE1 4097/4885 |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | HSD17B10 548/4885MME 3490/4885ECE1 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.